ANN ARBOR, Mich., Dec. 16, 2010 /PRNewswire-FirstCall/ —
Adeona Pharmaceuticals, Inc. (NYSE Amex:
AEN), a developer of innovative medicines for serious central
nervous system diseases, announced today that it has acquired
access to clinical data supporting a zinc-based therapy for the
prevention of infections in the elderly. This acquisition expands
and enhances Adeona’s zinc-based product candidate portfolio that
already includes its proprietary zinc-based tablets for use in the
dietary management of mild to moderate Alzheimer’s disease and mild
cognitive impairment patients, and age-related macular
degeneration. In addition, Adeona also announced the appointment of
the zinc research pioneer, Ananda S. Prasad, M.D., Ph.D., to the
Company’s Scientific Advisory Board.
“I am pleased to join the Scientific Advisory Board of Adeona, a
company leading the development of zinc-based therapies addressing
diseases in the elderly,” said Ananda S. Prasad, M.D., Ph.D. “I
look forward to providing guidance as Adeona moves their promising
zinc-based product candidates through development.”
Zinc for Prevention of Infection in the Elderly
Adeona has entered into an agreement with Dr. Prasad that
provides the Company with access to clinical data from a 50
patient, 12-month, randomized, double-blind, placebo-controlled
clinical trial that evaluated the prevention of infection in
patients age 55 to 87 who were treated with an oral zinc therapy
(45 mg elemental zinc per day away from food) or matching placebo.
The clinical trial was conducted by Dr. Prasad and
co-investigators. The primary endpoint of the clinical trial was
the rate of infections between the placebo and zinc treated groups.
The results at 12 months demonstrated a 67% reduction in the
incidence of infection between the two groups (88 infections in the
placebo group versus 29 infections in the zinc trea
‘/>”/>
SOURCE